Biocon Limited Q3 FY26 Earnings Call Transcript Released
Biocon Limited released its Q3 FY26 earnings call transcript, detailing a 9% YoY revenue growth to ₹4,173 crore and a 21% YoY EBITDA increase to ₹1,221 crore. The company highlighted the planned merger of Biocon Biologics with Biocon, valued at USD 5.5 billion. Key updates include new biosimilar oncology assets and the launch of generic Liraglutide. Credit ratings were upgraded, and structured debt was retired.
The announcement includes a detailed earnings call transcript, significant financial performance updates (revenue and EBITDA growth), strategic corporate actions (merger of Biocon Biologics with Biocon, debt retirement), pipeline advancements (new oncology assets, GLP-1 launches), and positive credit rating actions. These factors collectively have a substantial impact on investor perception and the company's financial outlook.
The company reported positive financial results with revenue and EBITDA growth, highlighted by strong performance in Biosimilars and Generics. Strategic moves like the planned merger of Biocon Biologics and debt reduction were positively received, as evidenced by credit rating upgrades. The overall tone of the earnings call and management commentary was optimistic about future growth and value creation.
Biocon Limited has released the transcript of its Q3 FY26 Earnings Call, which was held on February 13, 2026. The call featured key management personnel including Dr. Kiran Mazumdar Shaw, Executive Chairperson, and Mr. Siddharth Mittal, CEO & MD of Biocon Limited, along with leaders from Biocon Biologics Limited.
Key strategic discussions highlighted the planned merger of Biocon Biologics with Biocon, valuing Biocon Biologics at USD 5.5 billion and aiming to establish an integrated biopharma enterprise. This move is seen as aligning with India's Biopharma Shakti initiative. The company has also focused on strengthening its balance sheet through QIPs, raising nearly $1 billion to retire acquisition-related structured debt.
Financially, Biocon reported a 9% year-on-year growth in operating revenue to INR 4,173 crores for Q3 FY26. Core EBITDA increased by 21% year-on-year to INR 1,221 crores, with a margin of 29%. Biosimilars revenue grew by 9% to INR 2,497 crores, while Generics saw a strong 24% year-on-year growth to INR 851 crores. The CRDMO business experienced a 3% year-on-year decline in revenue to INR 917 crores.
Pipeline updates included the disclosure of three new biosimilar oncology assets: Trastuzumab sub Q, Nivolumab, and Pembrolizumab. The company also launched generic Liraglutide in the Netherlands and signed an out-licensing agreement with Ajanta Pharma for Semaglutide. Credit rating agencies S&P Global Ratings and Fitch Ratings upgraded their outlooks for Biocon Biologics, citing improved financial leverage.
During the Q&A, management addressed the upgrade of production and quality facilities for biosimilars, emphasizing its role in scaling up to meet increased demand and preserve margins. Discussions also covered capex moderation, with future investments primarily focused on maintenance. The company confirmed the retirement of all structured debt and a significant reduction in interest costs. The rationale for acquiring full global rights for Hulio (adalimumab) was explained as integrating a successful, over USD 200 million franchise into their portfolio. Updates on GLP-1 molecule filings and approvals in Canada and other markets were also provided, along with progress on insulin aspart commercial scale-up.
What to do with a filing like this
Biocon Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Biocon Limited. Read the original for the full detail.